Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccination timing and mRNA vaccine choice in recovered hospitalized COVID-19 patients from ACTIV-3/TICO
2021-003386-35Phase 4Terminated
- Sponsor
- Regents of the University of Minesota
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tozinameran and elasomeran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Regents of the University of Minesota. Started Jul 2021; status: terminated.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-003386-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003386-35.